RxDoctor Payments Data

Miguel Loya, DO

Internal Medicine · Solvang, CANPI 1619281532

Payments from drug & device makers

$779in general payments, 2019–2025

Across 57 payments — averaging $13.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$163
  • AbbVie$146
  • Supernus Pharmaceuticals, Inc.$114
  • Boehringer Ingelheim$95
  • Sanofi-aventis U.S. LLC$40
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$36
  • plus $185 from 12 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$779 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$194,726
Medicare patients
479
Services billed
6,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$105,424
OzempicSemaglutide71$66,448
EliquisApixaban65$61,795
CreonLipase/Protease/Amylase12$47,824
XareltoRivaroxaban53$40,986
MounjaroTirzepatide32$33,765
TrulicityDulaglutide19$26,239
RybelsusSemaglutide17$17,078
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr40$16,574
Breo ElliptaFluticasone/Vilanterol13$7,985
Celecoxib119$5,766
Losartan Potassium379$4,535
Bupropion XlBupropion Hcl131$3,694
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$3,681
Levothyroxine Sodium289$3,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$95$105,424124 claims
Novo NordiskOzempic, Rybelsus$14$83,52788 claims
PfizerEliquis$163$61,79565 claims
Lilly USA, LLCMounjaro, Trulicity$14$60,00451 claims
AbbVieCreon$146$47,82412 claims
Johnson & JohnsonXarelto$15$40,98653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Solvang

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →